<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547101</url>
  </required_header>
  <id_info>
    <org_study_id>AK104-205</org_study_id>
    <nct_id>NCT04547101</nct_id>
  </id_info>
  <brief_title>A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors</brief_title>
  <official_title>A Single-arm, Open-label, Multicenter, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akeso Pharmaceuticals, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy,&#xD;
      pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with&#xD;
      previously-treated locally advanced unresectable or metastatic MSI-H or dMMR solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the proportion of subjects with confirmed CR, PR, or SD, based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS is defined as the time from the start of treatment with AK104 until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>From first dose of AK104 through to 90 days after last dose of AK104</time_frame>
    <description>Incidences of treatment-emergent adverse events (TEAEs) , treatment-related adverse events (TRAEs) as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pharmacokinetics (PK) exposure of AK104</measure>
    <time_frame>From first dose of AK104 through to 90 days after last dose of AK104</time_frame>
    <description>The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK104 through to 90 days after last dose of AK104</time_frame>
    <description>The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable ADAs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>MSI-H/dMMR Solid Tumor</condition>
  <arm_group>
    <arm_group_label>AK104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK104</intervention_name>
    <description>AK104，6 mg/kg IV，every 2 weeks (Q2W)</description>
    <arm_group_label>AK104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed written informed consent form voluntarily.&#xD;
&#xD;
          -  Male or female, age ≥ 18 years on the day of signing informed consent form.&#xD;
&#xD;
          -  ECOG of 0 or 1.&#xD;
&#xD;
          -  Estimated life expectancy of ≥3 months.&#xD;
&#xD;
          -  Histologically or cytologically documented locally advanced unresectable or metastatic&#xD;
             solid tumors.&#xD;
&#xD;
          -  Confirmed MSI-H/dMMR status by the central laboratory.&#xD;
&#xD;
          -  Have experienced documented disease progression during or after at least first-line&#xD;
             therapy.&#xD;
&#xD;
          -  Have radiologically measurable disease based on RECIST 1.1.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Have agreed to take effective contraception from the date of signing the informed&#xD;
             consent form until 120 days after the last administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of investigational products or devices within 4 weeks prior to C1D1 (Cycle 1&#xD;
             Day 1, the first dose of study drug).&#xD;
&#xD;
          -  Presence of active autoimmune disease that have received systematic treatment in the&#xD;
             past 2 years; or that is judged to be possibly relapsed or requires planned treatment&#xD;
             by investigators.&#xD;
&#xD;
          -  Active inflammatory bowel disease or that required treatment (e.g. Crohn's disease,&#xD;
             ulcerative colitis or chronic diarrhea).&#xD;
&#xD;
          -  Prior use of systematic corticosteroid (&gt; 10 mg daily prednisone equivalents) or other&#xD;
             immunosuppressive medications within 14 days prior to C1D1.&#xD;
&#xD;
          -  Prior exposure to tumor immunotherapy, such as checkpoint inhibitors (eg. anti-PD-1,&#xD;
             anti-PD-L1, anti-CTLA-4 antibody), checkpoint agonists or cellular therapy.&#xD;
&#xD;
          -  Known history of allogeneic organ transplantation or allogeneic hematopoietic stem&#xD;
             cell transplantation.&#xD;
&#xD;
          -  Known presence or history of interstitial lung disease.&#xD;
&#xD;
          -  History of gastrointestinal perforation and/or fistula within 6 months prior to C1D1.&#xD;
&#xD;
          -  Serious infections within 4 weeks prior to C1D1.&#xD;
&#xD;
          -  Known presence of active tuberculosis.&#xD;
&#xD;
          -  Known untreated chronic hepatitis B or chronic hepatitis B virus DNA exceeding 1000&#xD;
             IU/ mL or active hepatitis C virus.&#xD;
&#xD;
          -  Receipt of recent radiotherapy or anti-tumor treatment within 4 weeks prior to C1D1.&#xD;
&#xD;
          -  Presence of meningeal metastasis, spinal cord compression, leptomeningeal disease or&#xD;
             central nervous system metastasis, with some exceptions.&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage.&#xD;
&#xD;
          -  Unresolved toxicities from prior anticancer therapy, defined as having not resolved to&#xD;
             NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion&#xD;
             criteria. Hair loss is excluded&#xD;
&#xD;
          -  Known history of sever hypersensitivity reaction to other monoclonal antibodies.&#xD;
&#xD;
          -  Known history of allergy or hypersensitivity to AK104 or any of its components.&#xD;
&#xD;
          -  Any conditions that, in the investigator's opinion, may put subjects treated with the&#xD;
             study drug at risks, or interfere with the evaluation of study drug or subject safety,&#xD;
             or the interpretation of results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruihua Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoping Jin, PhD</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, M.D</last_name>
      <phone>+86 (020) 8734 3333</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

